查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1595262

勝胜肽抗生素市場：按類型、疾病、給藥途徑、分銷管道分類 - 全球預測 2025-2030

Peptide Antibiotics Market by Type, Disease, Route of Administration, Distribution Channel - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 195 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

勝胜肽抗生素市場2023年估值為51.1億美元，預計2024年將達到55.8億美元，複合年成長率為9.74%，預計2030年將達到98億美元。

胜肽抗生素是抗菌領域中的利基但快速成長的領域，包括具有抗菌特性的天然衍生或合成工程的胜肽基化合物。它們的範圍主要取決於它們對抗多重抗藥性（MDR）病原體的能力，這使它們成為應對日益嚴重的全球抗生素抗藥性危機的重要工具。對胜肽抗生素的需求源於其獨特的作用機制，該機制針對細菌膜並降低抗藥性。特別是可望應用於農業治療院內感染等嚴重感染疾病，以及防治動植物病害。勝胜肽抗生素的最終用途範圍涵蓋藥品、農業生物技術和個人保健產品。

主要市場統計
基準年[2023] 51.1億美元
預測年份 [2024] 55.8億美元
預測年份 [2030] 98億美元
複合年成長率（%） 9.74%

胜肽抗生素市場的促進因素包括對新型抗菌藥物的迫切需求、MDR細菌數量的增加以及胜肽技術研發投資的增加。一個主要的發展機會在於開發具有增強的穩定性和活性頻譜的下一代勝胜肽抗生素。然而，市場面臨生產成本高、潛在毒性以及與核准新抗菌藥物相關的監管障礙等限制。此外，胜肽在體內的半衰期短也構成了需要創新解決方案的重大挑戰。

為了抓住市場機遇，公司應專注於提高穩定性和降低毒性的勝胜肽合成技術的進步，並與生物技術公司和研究機構建立策略聯盟。促進重組DNA技術等勝胜肽工程平台的研究和探索混合胜肽也可以突破當前的限制。此外，透過專注於個人化醫療，我們可以利用胜肽抗生素的特異性來提供量身定做的治療方案。該市場的特點是快速的科學進步和競爭格局，呈現出充滿活力但充滿挑戰的格局。投資尖端研究、簡化監管途徑並積極開展研究合作的公司可能會在這個充滿前景的市場中站穩腳跟。

市場動態：揭示快速發展的勝胜肽抗生素市場的關鍵市場洞察

供需的動態交互作用正在改變勝胜肽抗生素市場。透過了解這些不斷變化的市場動態，公司可以準備好做出明智的投資決策、完善策略決策並抓住新的商機。全面了解這些趨勢可以幫助企業降低政治、地理、技術、社會和經濟領域的風險，同時消費行為及其對製造成本的影響以及對採購趨勢的影響。

  • 市場促進因素
    • 細菌性皮膚感染疾病、血液感染疾病和醫院感染等疾病的盛行率增加
    • 醫院和診所對勝胜肽抗生素的需求不斷成長
    • 改善醫療基礎設施
  • 市場限制因素
    • 嚴格的報銷政策
  • 市場機會
    • 增加產品核可、產品發布和舉措
    • 在皮膚/骨骼再生、預防植入相關感染疾病、癌症治療和基因轉移方面的新用途
  • 市場挑戰
    • 對胜肽抗生素不穩定性和毒性的擔憂

波特五力：駕馭勝胜肽抗生素市場的策略工具

波特的五力框架是了解勝胜肽抗生素市場競爭格局的關鍵工具。波特的五力框架為評估公司的競爭地位和探索策略機會提供了清晰的方法。該框架可幫助公司評估市場動態並確定新業務的盈利。這些見解使公司能夠利用自己的優勢，解決弱點並避免潛在的挑戰，從而確保更強大的市場地位。

PESTLE分析：了解勝胜肽抗生素市場的外部影響

外部宏觀環境因素在塑造勝胜肽抗生素市場的表現動態方面發揮著至關重要的作用。對政治、經濟、社會、技術、法律和環境因素的分析提供了應對這些影響所需的資訊。透過調查 PESTLE 因素，公司可以更了解潛在的風險和機會。這種分析可以幫助公司預測法規、消費者偏好和經濟趨勢的變化，並為他們做出積極主動的決策做好準備。

市場佔有率分析 了解勝胜肽抗生素市場競爭狀況

對胜肽抗生素市場的詳細市場佔有率分析可以對供應商的績效進行全面評估。公司可以透過比較收益、客戶群和成長率等關鍵指標來揭示其競爭地位。該分析揭示了市場集中、分散和整合的趨勢，為供應商提供了製定策略決策所需的洞察力，使他們能夠在日益激烈的競爭中佔有一席之地。

FPNV定位基質勝胜肽抗生素市場供應商績效評估

FPNV定位矩陣是評估勝胜肽抗生素市場供應商的重要工具。此矩陣允許業務組織根據商務策略和產品滿意度評估供應商，從而做出與其目標相符的明智決策。這四個象限使您能夠清晰、準確地分類供應商，以確定最能滿足您的策略目標的合作夥伴和解決方案。

策略分析和建議描繪了勝胜肽抗生素市場的成功之路

對於旨在加強其在全球市場的影響力的公司來說，對胜肽抗生素市場的策略分析至關重要。透過考慮關鍵資源、能力和績效指標，公司可以識別成長機會並努力改進。這種方法使您能夠克服競爭環境中的挑戰，利用新的商機並取得長期成功。

本報告對市場進行了全面分析，涵蓋關鍵重點領域：

1. 市場滲透率：對當前市場環境的詳細審查、主要企業的廣泛資料、對其在市場中的影響力和整體影響力的評估。

2. 市場開拓：辨識新興市場的成長機會，評估現有領域的擴張潛力，並提供未來成長的策略藍圖。

3. 市場多元化：分析近期產品發布、開拓地區、關鍵產業進展、塑造市場的策略投資。

4. 競爭評估與情報：全面分析競爭格局，檢驗市場佔有率、業務策略、產品系列、認證、監管核准、專利趨勢、主要企業的技術進步等。

5.產品開發與創新：重點關注可望推動未來市場成長的最尖端科技、研發活動和產品創新。

我們也回答重要問題，以幫助相關人員做出明智的決策：

1.目前的市場規模和未來的成長預測是多少？

2. 哪些產品、區隔市場和地區提供最佳投資機會？

3.塑造市場的主要技術趨勢和監管影響是什麼？

4.主要廠商的市場佔有率和競爭地位如何？

5. 推動供應商市場進入和退出策略的收益來源和策略機會是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 細菌性皮膚感染疾病、血液感染疾病和醫院感染等疾病的盛行率增加
      • 醫院和診所對胜肽抗生素的需求增加
      • 改善醫療基礎設施
    • 抑制因素
      • 嚴格的退費政策
    • 機會
      • 增加產品核可、產品發布和研發活動
      • 在皮膚和骨骼再生、預防植入相關感染疾病、癌症治療和基因傳遞方面的新應用
    • 任務
      • 對胜肽抗生素不穩定性和毒性的擔憂
  • 市場區隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 經濟
    • 社群
    • 技術的
    • 合法地
    • 環境

第6章勝胜肽抗生素市場：依類型

  • 非核醣體合成勝胜肽抗生素
  • 核醣體合成的胜肽抗生素

第7章勝胜肽抗生素市場：依疾病分類

  • 血流感染疾病
  • HABP/VABP
  • 皮膚感染疾病

第8章勝胜肽抗生素市場：依給藥途徑

  • 可注射的
  • 口服
  • 話題

第9章勝胜肽抗生素市場：依通路分類

  • 醫院藥房
  • 網路藥房
  • 零售藥房

第10章美洲胜肽抗生素市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第11章亞太胜肽抗生素市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第12章歐洲、中東和非洲胜肽抗生素市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第13章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
  • 戰略分析和建議

公司名單

  • Abbott Laboratories
  • AbbVie Inc.
  • Dr. Reddy's Laboratories Ltd.
  • Eli Lilly & Company
  • Eugia US LLC
  • Fresenius SE & Co. KGaA
  • GlaxoSmithKline PLC
  • Merck & Co., Inc.
  • Novartis AG
  • Novo Holdings A/S
  • Pfizer Inc.
  • Sanofi SA
  • Savara Inc.
  • Teva Pharmaceutical Industries Ltd.
  • Theravance Biopharma
Product Code: MRR-205091A88A0F

The Peptide Antibiotics Market was valued at USD 5.11 billion in 2023, expected to reach USD 5.58 billion in 2024, and is projected to grow at a CAGR of 9.74%, to USD 9.80 billion by 2030.

Peptide antibiotics, a niche yet burgeoning segment within the antimicrobial field, encompass naturally derived or synthetically engineered peptide-based compounds with antibacterial properties. Their scope is primarily defined by their ability to combat multi-drug resistant (MDR) pathogens, serving as a crucial tool in the growing global antibiotic resistance crisis. The necessity of peptide antibiotics arises from their unique mechanisms of action, targeting bacterial membranes and resulting in lower rates of resistance. They find applications across clinical settings for treating severe infections, particularly in hospital-acquired infections, and show promise in agriculture to prevent and treat plant and animal diseases. The end-use scope of peptide antibiotics spans pharmaceuticals, agricultural biotechnology, and personal care products.

KEY MARKET STATISTICS
Base Year [2023] USD 5.11 billion
Estimated Year [2024] USD 5.58 billion
Forecast Year [2030] USD 9.80 billion
CAGR (%) 9.74%

The market for peptide antibiotics is driven by the urgent need for novel antimicrobial agents, increased prevalence of MDR bacteria, and rising investment in research and development of peptide technologies. Key opportunities lie in the development of next-generation peptide antibiotics with enhanced stability and spectrum of activity. However, the market faces limitations such as high production costs, potential toxicity, and regulatory hurdles associated with the approval of new antimicrobial agents. Additionally, the short half-life of peptides in vivo poses a significant challenge that requires innovative solutions.

To capitalize on market opportunities, firms should focus on advancing peptide synthesis technologies to enhance stability and reduce toxicity, and fostering strategic collaborations with biotechnology companies and research institutions. Promoting research in peptide-engineering platforms like recombinant DNA technology and exploring hybrid peptides can also push the boundaries of current limitations. Further, a focus on personalized medicine could leverage the specificity of peptide antibiotics, offering tailored therapeutic options. The market is characterized by rapid scientific advancements and competitive pressures, indicating a vibrant yet challenging landscape. Companies that invest in cutting-edge research, streamline regulatory pathways, and engage in active collaborations are likely to gain a foothold in this promising market.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Peptide Antibiotics Market

The Peptide Antibiotics Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Increasing prevalence of diseases such as bacterial skin, blood stream, and hospital acquired infections
    • Rising need for peptide antibiotics in hospitals and clinics
    • Improvement in healthcare infrastructure facility
  • Market Restraints
    • Stringent reimbursement policy
  • Market Opportunities
    • Rising product approvals and product launches and R&D initiatives
    • Emerging use in regeneration of skin/bone, prevention of implant-associated infections, cancer therapy and gene delivery
  • Market Challenges
    • Concerns related to instability and toxicity of peptide antibiotics

Porter's Five Forces: A Strategic Tool for Navigating the Peptide Antibiotics Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Peptide Antibiotics Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Peptide Antibiotics Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Peptide Antibiotics Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Peptide Antibiotics Market

A detailed market share analysis in the Peptide Antibiotics Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Peptide Antibiotics Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Peptide Antibiotics Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Peptide Antibiotics Market

A strategic analysis of the Peptide Antibiotics Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Peptide Antibiotics Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, AbbVie Inc., Dr. Reddy's Laboratories Ltd., Eli Lilly & Company, Eugia US LLC, Fresenius SE & Co. KGaA, GlaxoSmithKline PLC, Merck & Co., Inc., Novartis AG, Novo Holdings A/S, Pfizer Inc., Sanofi S.A., Savara Inc., Teva Pharmaceutical Industries Ltd., and Theravance Biopharma.

Market Segmentation & Coverage

This research report categorizes the Peptide Antibiotics Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Type, market is studied across Non-Ribosomal Synthesized Peptide Antibiotics and Ribosomal Synthesized Peptide Antibiotics.
  • Based on Disease, market is studied across Blood Stream Infections, HABP/VABP, and Skin Infections.
  • Based on Route of Administration, market is studied across Injectable, Oral, and Topical.
  • Based on Distribution Channel, market is studied across Hospital Pharmacies, Online Pharmacies, and Retail Pharmacies.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increasing prevalence of diseases such as bacterial skin, blood stream, and hospital acquired infections
      • 5.1.1.2. Rising need for peptide antibiotics in hospitals and clinics
      • 5.1.1.3. Improvement in healthcare infrastructure facility
    • 5.1.2. Restraints
      • 5.1.2.1. Stringent reimbursement policy
    • 5.1.3. Opportunities
      • 5.1.3.1. Rising product approvals and product launches and R&D initiatives
      • 5.1.3.2. Emerging use in regeneration of skin/bone, prevention of implant-associated infections, cancer therapy and gene delivery
    • 5.1.4. Challenges
      • 5.1.4.1. Concerns related to instability and toxicity of peptide antibiotics
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Peptide Antibiotics Market, by Type

  • 6.1. Introduction
  • 6.2. Non-Ribosomal Synthesized Peptide Antibiotics
  • 6.3. Ribosomal Synthesized Peptide Antibiotics

7. Peptide Antibiotics Market, by Disease

  • 7.1. Introduction
  • 7.2. Blood Stream Infections
  • 7.3. HABP/VABP
  • 7.4. Skin Infections

8. Peptide Antibiotics Market, by Route of Administration

  • 8.1. Introduction
  • 8.2. Injectable
  • 8.3. Oral
  • 8.4. Topical

9. Peptide Antibiotics Market, by Distribution Channel

  • 9.1. Introduction
  • 9.2. Hospital Pharmacies
  • 9.3. Online Pharmacies
  • 9.4. Retail Pharmacies

10. Americas Peptide Antibiotics Market

  • 10.1. Introduction
  • 10.2. Argentina
  • 10.3. Brazil
  • 10.4. Canada
  • 10.5. Mexico
  • 10.6. United States

11. Asia-Pacific Peptide Antibiotics Market

  • 11.1. Introduction
  • 11.2. Australia
  • 11.3. China
  • 11.4. India
  • 11.5. Indonesia
  • 11.6. Japan
  • 11.7. Malaysia
  • 11.8. Philippines
  • 11.9. Singapore
  • 11.10. South Korea
  • 11.11. Taiwan
  • 11.12. Thailand
  • 11.13. Vietnam

12. Europe, Middle East & Africa Peptide Antibiotics Market

  • 12.1. Introduction
  • 12.2. Denmark
  • 12.3. Egypt
  • 12.4. Finland
  • 12.5. France
  • 12.6. Germany
  • 12.7. Israel
  • 12.8. Italy
  • 12.9. Netherlands
  • 12.10. Nigeria
  • 12.11. Norway
  • 12.12. Poland
  • 12.13. Qatar
  • 12.14. Russia
  • 12.15. Saudi Arabia
  • 12.16. South Africa
  • 12.17. Spain
  • 12.18. Sweden
  • 12.19. Switzerland
  • 12.20. Turkey
  • 12.21. United Arab Emirates
  • 12.22. United Kingdom

13. Competitive Landscape

  • 13.1. Market Share Analysis, 2023
  • 13.2. FPNV Positioning Matrix, 2023
  • 13.3. Competitive Scenario Analysis
  • 13.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Abbott Laboratories
  • 2. AbbVie Inc.
  • 3. Dr. Reddy's Laboratories Ltd.
  • 4. Eli Lilly & Company
  • 5. Eugia US LLC
  • 6. Fresenius SE & Co. KGaA
  • 7. GlaxoSmithKline PLC
  • 8. Merck & Co., Inc.
  • 9. Novartis AG
  • 10. Novo Holdings A/S
  • 11. Pfizer Inc.
  • 12. Sanofi S.A.
  • 13. Savara Inc.
  • 14. Teva Pharmaceutical Industries Ltd.
  • 15. Theravance Biopharma

LIST OF FIGURES

  • FIGURE 1. PEPTIDE ANTIBIOTICS MARKET RESEARCH PROCESS
  • FIGURE 2. PEPTIDE ANTIBIOTICS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL PEPTIDE ANTIBIOTICS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL PEPTIDE ANTIBIOTICS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL PEPTIDE ANTIBIOTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL PEPTIDE ANTIBIOTICS MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL PEPTIDE ANTIBIOTICS MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL PEPTIDE ANTIBIOTICS MARKET SIZE, BY DISEASE, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL PEPTIDE ANTIBIOTICS MARKET SIZE, BY DISEASE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL PEPTIDE ANTIBIOTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL PEPTIDE ANTIBIOTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL PEPTIDE ANTIBIOTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL PEPTIDE ANTIBIOTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. AMERICAS PEPTIDE ANTIBIOTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 15. AMERICAS PEPTIDE ANTIBIOTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. UNITED STATES PEPTIDE ANTIBIOTICS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 17. UNITED STATES PEPTIDE ANTIBIOTICS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC PEPTIDE ANTIBIOTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. ASIA-PACIFIC PEPTIDE ANTIBIOTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. EUROPE, MIDDLE EAST & AFRICA PEPTIDE ANTIBIOTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 21. EUROPE, MIDDLE EAST & AFRICA PEPTIDE ANTIBIOTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. PEPTIDE ANTIBIOTICS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 23. PEPTIDE ANTIBIOTICS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. PEPTIDE ANTIBIOTICS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL PEPTIDE ANTIBIOTICS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL PEPTIDE ANTIBIOTICS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL PEPTIDE ANTIBIOTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. PEPTIDE ANTIBIOTICS MARKET DYNAMICS
  • TABLE 7. GLOBAL PEPTIDE ANTIBIOTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL PEPTIDE ANTIBIOTICS MARKET SIZE, BY NON-RIBOSOMAL SYNTHESIZED PEPTIDE ANTIBIOTICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL PEPTIDE ANTIBIOTICS MARKET SIZE, BY RIBOSOMAL SYNTHESIZED PEPTIDE ANTIBIOTICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL PEPTIDE ANTIBIOTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL PEPTIDE ANTIBIOTICS MARKET SIZE, BY BLOOD STREAM INFECTIONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL PEPTIDE ANTIBIOTICS MARKET SIZE, BY HABP/VABP, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL PEPTIDE ANTIBIOTICS MARKET SIZE, BY SKIN INFECTIONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL PEPTIDE ANTIBIOTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL PEPTIDE ANTIBIOTICS MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL PEPTIDE ANTIBIOTICS MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL PEPTIDE ANTIBIOTICS MARKET SIZE, BY TOPICAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL PEPTIDE ANTIBIOTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL PEPTIDE ANTIBIOTICS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL PEPTIDE ANTIBIOTICS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL PEPTIDE ANTIBIOTICS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. AMERICAS PEPTIDE ANTIBIOTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 23. AMERICAS PEPTIDE ANTIBIOTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 24. AMERICAS PEPTIDE ANTIBIOTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 25. AMERICAS PEPTIDE ANTIBIOTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 26. AMERICAS PEPTIDE ANTIBIOTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 27. ARGENTINA PEPTIDE ANTIBIOTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 28. ARGENTINA PEPTIDE ANTIBIOTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 29. ARGENTINA PEPTIDE ANTIBIOTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 30. ARGENTINA PEPTIDE ANTIBIOTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 31. BRAZIL PEPTIDE ANTIBIOTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 32. BRAZIL PEPTIDE ANTIBIOTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 33. BRAZIL PEPTIDE ANTIBIOTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 34. BRAZIL PEPTIDE ANTIBIOTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 35. CANADA PEPTIDE ANTIBIOTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 36. CANADA PEPTIDE ANTIBIOTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 37. CANADA PEPTIDE ANTIBIOTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 38. CANADA PEPTIDE ANTIBIOTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 39. MEXICO PEPTIDE ANTIBIOTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 40. MEXICO PEPTIDE ANTIBIOTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 41. MEXICO PEPTIDE ANTIBIOTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 42. MEXICO PEPTIDE ANTIBIOTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 43. UNITED STATES PEPTIDE ANTIBIOTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 44. UNITED STATES PEPTIDE ANTIBIOTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 45. UNITED STATES PEPTIDE ANTIBIOTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 46. UNITED STATES PEPTIDE ANTIBIOTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 47. UNITED STATES PEPTIDE ANTIBIOTICS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 48. ASIA-PACIFIC PEPTIDE ANTIBIOTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 49. ASIA-PACIFIC PEPTIDE ANTIBIOTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 50. ASIA-PACIFIC PEPTIDE ANTIBIOTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 51. ASIA-PACIFIC PEPTIDE ANTIBIOTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 52. ASIA-PACIFIC PEPTIDE ANTIBIOTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 53. AUSTRALIA PEPTIDE ANTIBIOTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 54. AUSTRALIA PEPTIDE ANTIBIOTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 55. AUSTRALIA PEPTIDE ANTIBIOTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 56. AUSTRALIA PEPTIDE ANTIBIOTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 57. CHINA PEPTIDE ANTIBIOTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 58. CHINA PEPTIDE ANTIBIOTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 59. CHINA PEPTIDE ANTIBIOTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 60. CHINA PEPTIDE ANTIBIOTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 61. INDIA PEPTIDE ANTIBIOTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 62. INDIA PEPTIDE ANTIBIOTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 63. INDIA PEPTIDE ANTIBIOTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 64. INDIA PEPTIDE ANTIBIOTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 65. INDONESIA PEPTIDE ANTIBIOTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 66. INDONESIA PEPTIDE ANTIBIOTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 67. INDONESIA PEPTIDE ANTIBIOTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 68. INDONESIA PEPTIDE ANTIBIOTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 69. JAPAN PEPTIDE ANTIBIOTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 70. JAPAN PEPTIDE ANTIBIOTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 71. JAPAN PEPTIDE ANTIBIOTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 72. JAPAN PEPTIDE ANTIBIOTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 73. MALAYSIA PEPTIDE ANTIBIOTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 74. MALAYSIA PEPTIDE ANTIBIOTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 75. MALAYSIA PEPTIDE ANTIBIOTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 76. MALAYSIA PEPTIDE ANTIBIOTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 77. PHILIPPINES PEPTIDE ANTIBIOTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 78. PHILIPPINES PEPTIDE ANTIBIOTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 79. PHILIPPINES PEPTIDE ANTIBIOTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 80. PHILIPPINES PEPTIDE ANTIBIOTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 81. SINGAPORE PEPTIDE ANTIBIOTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 82. SINGAPORE PEPTIDE ANTIBIOTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 83. SINGAPORE PEPTIDE ANTIBIOTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 84. SINGAPORE PEPTIDE ANTIBIOTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 85. SOUTH KOREA PEPTIDE ANTIBIOTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 86. SOUTH KOREA PEPTIDE ANTIBIOTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 87. SOUTH KOREA PEPTIDE ANTIBIOTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 88. SOUTH KOREA PEPTIDE ANTIBIOTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 89. TAIWAN PEPTIDE ANTIBIOTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 90. TAIWAN PEPTIDE ANTIBIOTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 91. TAIWAN PEPTIDE ANTIBIOTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 92. TAIWAN PEPTIDE ANTIBIOTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 93. THAILAND PEPTIDE ANTIBIOTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 94. THAILAND PEPTIDE ANTIBIOTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 95. THAILAND PEPTIDE ANTIBIOTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 96. THAILAND PEPTIDE ANTIBIOTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 97. VIETNAM PEPTIDE ANTIBIOTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 98. VIETNAM PEPTIDE ANTIBIOTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 99. VIETNAM PEPTIDE ANTIBIOTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 100. VIETNAM PEPTIDE ANTIBIOTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 101. EUROPE, MIDDLE EAST & AFRICA PEPTIDE ANTIBIOTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 102. EUROPE, MIDDLE EAST & AFRICA PEPTIDE ANTIBIOTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 103. EUROPE, MIDDLE EAST & AFRICA PEPTIDE ANTIBIOTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 104. EUROPE, MIDDLE EAST & AFRICA PEPTIDE ANTIBIOTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 105. EUROPE, MIDDLE EAST & AFRICA PEPTIDE ANTIBIOTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 106. DENMARK PEPTIDE ANTIBIOTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 107. DENMARK PEPTIDE ANTIBIOTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 108. DENMARK PEPTIDE ANTIBIOTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 109. DENMARK PEPTIDE ANTIBIOTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 110. EGYPT PEPTIDE ANTIBIOTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 111. EGYPT PEPTIDE ANTIBIOTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 112. EGYPT PEPTIDE ANTIBIOTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 113. EGYPT PEPTIDE ANTIBIOTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 114. FINLAND PEPTIDE ANTIBIOTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 115. FINLAND PEPTIDE ANTIBIOTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 116. FINLAND PEPTIDE ANTIBIOTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 117. FINLAND PEPTIDE ANTIBIOTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 118. FRANCE PEPTIDE ANTIBIOTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 119. FRANCE PEPTIDE ANTIBIOTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 120. FRANCE PEPTIDE ANTIBIOTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 121. FRANCE PEPTIDE ANTIBIOTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 122. GERMANY PEPTIDE ANTIBIOTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 123. GERMANY PEPTIDE ANTIBIOTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 124. GERMANY PEPTIDE ANTIBIOTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 125. GERMANY PEPTIDE ANTIBIOTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 126. ISRAEL PEPTIDE ANTIBIOTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 127. ISRAEL PEPTIDE ANTIBIOTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 128. ISRAEL PEPTIDE ANTIBIOTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 129. ISRAEL PEPTIDE ANTIBIOTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 130. ITALY PEPTIDE ANTIBIOTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 131. ITALY PEPTIDE ANTIBIOTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 132. ITALY PEPTIDE ANTIBIOTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 133. ITALY PEPTIDE ANTIBIOTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 134. NETHERLANDS PEPTIDE ANTIBIOTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 135. NETHERLANDS PEPTIDE ANTIBIOTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 136. NETHERLANDS PEPTIDE ANTIBIOTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 137. NETHERLANDS PEPTIDE ANTIBIOTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 138. NIGERIA PEPTIDE ANTIBIOTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 139. NIGERIA PEPTIDE ANTIBIOTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 140. NIGERIA PEPTIDE ANTIBIOTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 141. NIGERIA PEPTIDE ANTIBIOTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 142. NORWAY PEPTIDE ANTIBIOTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 143. NORWAY PEPTIDE ANTIBIOTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 144. NORWAY PEPTIDE ANTIBIOTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 145. NORWAY PEPTIDE ANTIBIOTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 146. POLAND PEPTIDE ANTIBIOTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 147. POLAND PEPTIDE ANTIBIOTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 148. POLAND PEPTIDE ANTIBIOTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 149. POLAND PEPTIDE ANTIBIOTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 150. QATAR PEPTIDE ANTIBIOTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 151. QATAR PEPTIDE ANTIBIOTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 152. QATAR PEPTIDE ANTIBIOTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 153. QATAR PEPTIDE ANTIBIOTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 154. RUSSIA PEPTIDE ANTIBIOTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 155. RUSSIA PEPTIDE ANTIBIOTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 156. RUSSIA PEPTIDE ANTIBIOTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 157. RUSSIA PEPTIDE ANTIBIOTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 158. SAUDI ARABIA PEPTIDE ANTIBIOTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 159. SAUDI ARABIA PEPTIDE ANTIBIOTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 160. SAUDI ARABIA PEPTIDE ANTIBIOTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 161. SAUDI ARABIA PEPTIDE ANTIBIOTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 162. SOUTH AFRICA PEPTIDE ANTIBIOTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 163. SOUTH AFRICA PEPTIDE ANTIBIOTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 164. SOUTH AFRICA PEPTIDE ANTIBIOTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 165. SOUTH AFRICA PEPTIDE ANTIBIOTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 166. SPAIN PEPTIDE ANTIBIOTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 167. SPAIN PEPTIDE ANTIBIOTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 168. SPAIN PEPTIDE ANTIBIOTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 169. SPAIN PEPTIDE ANTIBIOTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 170. SWEDEN PEPTIDE ANTIBIOTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 171. SWEDEN PEPTIDE ANTIBIOTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 172. SWEDEN PEPTIDE ANTIBIOTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 173. SWEDEN PEPTIDE ANTIBIOTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 174. SWITZERLAND PEPTIDE ANTIBIOTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 175. SWITZERLAND PEPTIDE ANTIBIOTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 176. SWITZERLAND PEPTIDE ANTIBIOTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 177. SWITZERLAND PEPTIDE ANTIBIOTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 178. TURKEY PEPTIDE ANTIBIOTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 179. TURKEY PEPTIDE ANTIBIOTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 180. TURKEY PEPTIDE ANTIBIOTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 181. TURKEY PEPTIDE ANTIBIOTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 182. UNITED ARAB EMIRATES PEPTIDE ANTIBIOTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 183. UNITED ARAB EMIRATES PEPTIDE ANTIBIOTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 184. UNITED ARAB EMIRATES PEPTIDE ANTIBIOTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 185. UNITED ARAB EMIRATES PEPTIDE ANTIBIOTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 186. UNITED KINGDOM PEPTIDE ANTIBIOTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 187. UNITED KINGDOM PEPTIDE ANTIBIOTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 188. UNITED KINGDOM PEPTIDE ANTIBIOTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 189. UNITED KINGDOM PEPTIDE ANTIBIOTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 190. PEPTIDE ANTIBIOTICS MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 191. PEPTIDE ANTIBIOTICS MARKET, FPNV POSITIONING MATRIX, 2023